OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ASAR55

Asarfi Hospital Ltd

Healthcare Facilities & ServicesVerified

Asarfi Hospital Ltd has a basic capital structure with no dilution risk, as the number of basic and diluted shares outstanding is identical at 19,677,300. However, the liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in source documents. This lack of financial transparency limits the ability to evaluate the company's short-term financial health and operational resilience. Profitability and return metrics are not available for Asarfi Hospital Ltd, which makes it difficult to compare its performance against industry benchmarks or preferred metrics. Without data on return on invested capital (ROIC), operating margins, or net profit margins, it is impossible to gauge the company's efficiency or profitability relative to its peers. The company's revenue concentration and geographic exposure are not disclosed in the available data. This absence of segmental and geographic breakdowns prevents an assessment of potential risks from overreliance on specific markets or customer bases. Asarfi Hospital Ltd's exposure to regional economic or regulatory shifts remains opaque. Growth trajectory data is also unavailable, as no outlook figures or revenue history are provided. Without numeric deltas for the current or next fiscal year, it is impossible to determine whether the company is expanding, contracting, or maintaining its current revenue levels. This lack of forward-looking guidance hinders the ability to model future performance. Risk factors include the unassessed liquidity risk and the absence of disclosed dilution potential. The company's financial statements do not provide enough detail to evaluate its ability to meet short-term obligations or to identify potential sources of dilution such as share buybacks, new issuances, or convertible instruments. The lack of going-concern language in source documents raises concerns about the company's long-term viability. Recent events, including filings and transcripts, are not disclosed in the available data. This absence of recent activity makes it difficult to assess the company's strategic direction, management commentary, or any material developments that could impact its operations or financial position.

30-day price · ASAR+21.55 (+12.1%)
Low$167.55High$256.95Close$199.60As of12 May, 00:00 UTC
Profile
CompanyAsarfi Hospital Ltd
TickerASAR.BO
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Asarfi Hospital Ltd operates in the healthcare facilities and services industry, providing medical care and related services to patients.

Classification. Asarfi Hospital Ltd is classified under the Healthcare economic sector, Healthcare Services & Equipment business sector, and Healthcare Facilities & Services industry with a confidence level of 0.92.

Asarfi Hospital Ltd has a basic capital structure with no dilution risk, as the number of basic and diluted shares outstanding is identical at 19,677,300. However, the liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in source documents. This lack of financial transparency limits the ability to evaluate the company's short-term financial health and operational resilience. Profitability and return metrics are not available for Asarfi Hospital Ltd, which makes it difficult to compare its performance against industry benchmarks or preferred metrics. Without data on return on invested capital (ROIC), operating margins, or net profit margins, it is impossible to gauge the company's efficiency or profitability relative to its peers. The company's revenue concentration and geographic exposure are not disclosed in the available data. This absence of segmental and geographic breakdowns prevents an assessment of potential risks from overreliance on specific markets or customer bases. Asarfi Hospital Ltd's exposure to regional economic or regulatory shifts remains opaque. Growth trajectory data is also unavailable, as no outlook figures or revenue history are provided. Without numeric deltas for the current or next fiscal year, it is impossible to determine whether the company is expanding, contracting, or maintaining its current revenue levels. This lack of forward-looking guidance hinders the ability to model future performance. Risk factors include the unassessed liquidity risk and the absence of disclosed dilution potential. The company's financial statements do not provide enough detail to evaluate its ability to meet short-term obligations or to identify potential sources of dilution such as share buybacks, new issuances, or convertible instruments. The lack of going-concern language in source documents raises concerns about the company's long-term viability. Recent events, including filings and transcripts, are not disclosed in the available data. This absence of recent activity makes it difficult to assess the company's strategic direction, management commentary, or any material developments that could impact its operations or financial position.
Key takeaways
  • Asarfi Hospital Ltd has no dilution risk, as basic and diluted shares are equal.
  • Liquidity risk cannot be assessed due to missing balance-sheet data and no going-concern language.
  • Profitability and return metrics are not available, limiting performance benchmarking.
  • Revenue concentration and geographic exposure are undisclosed, increasing operational risk.
  • Growth trajectory and future revenue expectations are unknown due to missing outlook data.
  • Recent company events and strategic developments are not disclosed in the available data.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$541.2M$51.2M$35.3M-$19.2M
FY-3$652.1M$75.5M$58.2M-$103.5M
FY-2$707.0M$99.0M$80.2M-$82.5M
FY-1$844.0M$75.8M$41.6M-$331.2M
FY0$1.21B$117.0M$105.8M$134.0M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$372.9M$169.0M
FY-3$627.0M$229.6M
FY-2$934.2M$418.6M
FY-1$1.54B$704.1M
FY0$1.64B$809.8M
PeriodOCFCapExFCFSBC
FY-4$102.9M-$83.6M-$19.2M
FY-3$211.4M-$195.2M-$103.5M
FY-2$73.3M-$201.4M-$82.5M
FY-1$260.7M-$460.7M-$331.2M
FY0-$43.5M-$98.5M$134.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6$229.2M$15.7M$14.5M
FQ-5$308.6M$35.7M$28.5M
FQ-4$328.9M$39.0M$26.8M$7.0M
FQ-3$338.9M$18.2M$35.9M$47.9M
FQ-2$356.8M$40.0M$31.2M$50.9M
FQ-1$448.9M$59.6M$42.0M$30.5M
FQ0$461.0M$72.2M$54.2M$52.8M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5$1.58B$745.2M
FQ-4$1.65B$773.9M
FQ-3$1.64B$809.8M
FQ-2$1.66B$841.0M
FQ-1$1.72B$883.0M
FQ0$1.85B$937.3M
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5-$33.8M-$27.6M
FQ-4$23.4M-$78.0M$7.0M
FQ-3-$43.5M-$98.5M$47.9M
FQ-2$53.0M-$10.2M$50.9M
FQ-1$92.0M-$50.8M$30.5M
FQ0$108.5M-$81.1M$52.8M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricASARActivity
Op margin7.7% medp25 -2.4% · p75 15.5%
Net margin5.9% medp25 -3.8% · p75 12.8%
Gross margin45.5% medp25 31.1% · p75 62.9%
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-7.0% medp25 -14.9% · p75 -3.2%
Debt / equity25.0% medp25 3.8% · p75 63.3%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-12 01:03 UTC#fd241bb3
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 09:43 UTCJob: 82596418